Hims & Hers Health, Inc. (NYSE:HIMS) stock is trading lower on Wednesday, with a session volume of 7.7 million compared to ...

A holistic approach emphasizes lifestyle choices, nutrition, exercise, stress management, medications where appropriate, and ...

"The FDA's compounding program aims to protect patients from poor quality compounded drugs, while preserving access to lawfully marketed compounded drugs for patients." Before Hims & Hers ...

One popular option, Weight Loss by Hers, is a holistic program personalized for you. The program features four pillars of holistic weight loss, including nutrition, sleep, movement, and medication. It ...

BTIG analyst David Larsen contends that Hims & Hers' obesity care program will thrive despite the changes in the GLP-1 market. In an analyst note, Larsen estimated the company had about 100,000 ...

Hims & Hers reported its Q4 earnings this week. The company is growing quickly but faces a potential legal threat to its ...

Hims & Hers Health (NYSE: HIMS) has been a top healthcare stock to own over the past five years, soaring by around 350% during that stretch. By focusing on offering customers personalized ...

Shares of Hims & Hers Health (HIMS) tumbled 15% yesterday after Novo Nordisk (NVO) announced it was cutting the price of its GLP-1 weight-loss drug Wegovy by more than half. The move obliterates ...

HIMS stock is going bananas with the stock up nearly 200% YTD at one point. However, the stock sold off due to the FDA's announcement that semaglutide will be taken off the shortage list. While ...

Hims & Hers Health's stock has surged 205% since my last 'Buy' rating, but its valuation is now stretched, prompting a downgrade to 'Hold'. Some risks include Amazon's aggressive telehealth entry ...

Inc. HIMS stock is trading lower on Wednesday, with a session volume of 7.7 million compared to the average volume of 19.34 million, as per data from Benzinga Pro. The program offers all dosage ...